Arkstone’s technology now provides tracking, reporting and monitoring of infections across an entire facility to provide the most comprehensive ASP available
Arkstone works side-by-side with molecular laboratories, and the physicians they serve, to provide clarity and comprehension of diagnostic data. Through proprietary AI systems, advanced algorithms and machine learning, Arkstone’s OneChoice® decision engine delivers the most optimal treatment regimen with every microbiology result. Arkstone uses a multitude of references such as John Hopkins, CDC and IDSA in combination with infectious disease expertise as well as real-time quality assurance input, in order to provide the most up to date evidence based recommendations. Long term care facilities are utilizing laboratories that partner with Arkstone to take advantage of the advanced antimicrobial stewardship programs provided, along with technology that tracks, records, and monitors infection trends across their facilities.
“Although The Centers for Medicare & Medicaid Services (CMS), Centers for Disease Control and Prevention (CDC), and The Joint Commission advocate for these programs, many facilities do not have the expertise and backing to support robust and comprehensive stewardship programs,” says Sol Levi, co-founder and CCO. “ The new Antimicrobial Stewardship Monthly Report provides facilities with exactly what they need to have an optimal ASP and helps fulfill the requirements laid out by CMS and the Joint Commission.
The Antimicrobial Stewardship Monthly Report includes month-to-month tracking of infections from many different sources, including respiratory, wound, urine, and GI. The report breaks down the most common types of infections and resistance genes and analyzes this data so that trends are easily visible, allowing for the implementation of proactive surveillance and infection control policies. The reports also contain dynamic ASP checklists that are custom tailored to each sample source so that a facility can be confident that all the necessary measures and steps are being taken. Specific analysis of microbes of interest, such as COVID-19, C-diff, MRSA and influenza are focused on ensuring the right protocols are in place to avoid the spread of disease. In addition to specific drug expertise, quality improvement measures, treatment algorithms, ASP policies, and continuous education are provided as well as monthly educational newsletters.
“With the growing spread of antimicrobial resistance, ASP programs are essential to all healthcare facilities,” says Dr. Ari Frenkel, Arkstone’s Chief Science Officer and co-founder. “Our new Antimicrobial Stewardship Monthly Reports are designed to provide the most effective, and proactive ASP available. The fight against antibiotic resistance is a collaborative effort and we cannot win it without every healthcare provider and every healthcare facility actively engaged in this process. We believe this new feature can accomplish just that.”
Features of The Arkstone Antimicrobial Stewardship Monthly Report:
- Data monitoring, tracking and reporting
- Monthly specimen collection trends
- Positive result detection ratio analyzed
- Trends of common infections detected per facility
- Trends of common resistance genes detected per facility
- Specific monitoring of concerning pathogens
- Individual specimen source analysis
- Lab results summary including OneChoice® recommendations
- Policies and program implementation
- Treatment algorithms
- Infection control recommendations
- Infection alerts to prevent outbreaks
- Drug expertise
- Communication with providers via OneChoice® Report
- Targeted therapy and clarity on possible specimen contaminates or colonizers
- Antibiotic recommendations against specific pathogens
- Education
- Monthly educational newsletters
- Common pitfalls in testing and treating infections
- Statistics regarding common infections in long-term care facilities
Arkstone is committed to stem the global spread of antimicrobial resistance and the misuse of antibiotics by marrying advanced artificial intelligence with a deep understanding of infectious disease. Arkstone’s patent-pending OneChoice technology helps physicians practice precision-guided medicine through optimal treatment regimen recommendations. Additionally, the proprietary ArkScore system allows providers to compare antibiotics at a glance through an easy to understand visual score. Learn more at arkstone.ai or email info@arkstone.ai
###